Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT.

Br J Haematol. 2019 Aug 8. doi: 10.1111/bjh.16136. [Epub ahead of print] No abstract available.

PMID:
31396948
2.

Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor T-cell therapy.

Marzolini MAV, Jaunmuktane Z, Roddie C, O'Reilly M, Chiodini P, Peggs KS.

Lancet Infect Dis. 2019 Jul;19(7):788. doi: 10.1016/S1473-3099(19)30119-7. No abstract available.

PMID:
31250826
3.

In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review.

Chemaly RF, Hill JA, Voigt S, Peggs KS.

Antiviral Res. 2019 Mar;163:50-58. doi: 10.1016/j.antiviral.2019.01.008. Epub 2019 Jan 21. Review.

4.

Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, Sureda A, Patrick P, Clifton-Hadley L, Adedayo T, Kirkwood A, Peggs KS.

Br J Haematol. 2019 Mar;184(6):999-1005. doi: 10.1111/bjh.15723. Epub 2018 Dec 17.

PMID:
30560573
5.

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, Afanasyev B, Diez-Martin JL, Corradini P, Michonneau D, Robinson S, Gutiérrez García G, Bonifazi F, Yakoub-Agha I, Gülbas Z, Bloor A, Delage J, Esquirol A, Malladi R, Scheid C, El-Cheikh J, Ghesquières H, Montoto S, Dreger P, Sureda A.

Cancer. 2019 Jan 1;125(1):90-98. doi: 10.1002/cncr.31755. Epub 2018 Oct 23.

6.

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4.

Quezada SA, Peggs KS.

Clin Cancer Res. 2019 Feb 15;25(4):1130-1132. doi: 10.1158/1078-0432.CCR-18-2509. Epub 2018 Oct 5.

PMID:
30291135
7.

Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, Georgiou A, Furness AJS, Ben Aissa A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs TP, Kelly JD, Powles T, Peggs KS, Chain BM, Linch MD, Quezada SA.

J Exp Med. 2018 Nov 5;215(11):2748-2759. doi: 10.1084/jem.20181003. Epub 2018 Sep 26.

8.

Successful translation and future prospects of TALEN editing for leukemia patients.

Werner Sunderland M, Peggs KS.

Expert Opin Biol Ther. 2018 Jul;18(7):725-726. doi: 10.1080/14712598.2018.1484105. Epub 2018 Jun 14. No abstract available.

PMID:
29860877
9.

The function and dysfunction of memory CD8+ T cells in tumor immunity.

Reading JL, Gálvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA.

Immunol Rev. 2018 May;283(1):194-212. doi: 10.1111/imr.12657. Review.

PMID:
29664561
10.

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

Peggs KS.

Blood Adv. 2018 Apr 10;2(7):817-820. doi: 10.1182/bloodadvances.2017011122. Review. No abstract available.

11.

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.

Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA.

Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22.

12.

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, Bloor A, Martinez C, Robinson S, Malladi R, El-Cheikh J, Corradini P, Montoto S, Dreger P, Sureda A.

Br J Haematol. 2018 Apr;181(1):86-96. doi: 10.1111/bjh.15152. Epub 2018 Feb 22.

PMID:
29468647
13.

Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma.

Ghorani E, Rosenthal R, McGranahan N, Reading JL, Lynch M, Peggs KS, Swanton C, Quezada SA.

Ann Oncol. 2018 Jan 1;29(1):271-279. doi: 10.1093/annonc/mdx687.

14.

Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P.

Bone Marrow Transplant. 2018 May;53(5):617-624. doi: 10.1038/s41409-017-0067-3. Epub 2018 Jan 15.

PMID:
29335632
15.

Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG, Swanton C.

Nature. 2018 Feb 8;554(7691):264. doi: 10.1038/nature25161. Epub 2017 Dec 20.

PMID:
29258292
16.

Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA.

Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.

PMID:
29131157
17.

The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.

Joshi K, Chain BM, Peggs KS, Quezada SA.

Cold Spring Harb Perspect Med. 2018 Jan 2;8(1). pii: a027086. doi: 10.1101/cshperspect.a027086. Review.

PMID:
28630228
18.

Immunotherapy for transplantation-associated viral infections.

Roddie C, Peggs KS.

J Clin Invest. 2017 Jun 30;127(7):2513-2522. doi: 10.1172/JCI90599. Epub 2017 Jun 19. Review.

19.

Evolving adoptive cellular therapies in urological malignancies.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M.

Lancet Oncol. 2017 Jun;18(6):e341-e353. doi: 10.1016/S1470-2045(17)30327-3. Review.

PMID:
28593860
20.

Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C.

Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Erratum in: Nature. 2017 Dec 20;:.

21.

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.

Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA.

Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11.

22.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M.

Biol Blood Marrow Transplant. 2017 May;23(5):805-812. doi: 10.1016/j.bbmt.2017.02.007. Epub 2017 Feb 14.

23.

Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2013. doi: 10.1126/scitranslmed.aaj2013. Erratum in: Sci Transl Med. 2017 Feb 15;9(377):null.

PMID:
28123068
24.

Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS.

Bone Marrow Transplant. 2017 Mar;52(3):452-454. doi: 10.1038/bmt.2016.244. Epub 2017 Jan 16. No abstract available.

25.

Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?

Furness AJ, Quezada SA, Peggs KS.

Immunotherapy. 2016 Jun;8(7):763-6. doi: 10.2217/imt-2016-0064. No abstract available.

26.

A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM.

Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, Ardeshna KM, Virchis AE, Linch DC, Lambert J.

Bone Marrow Transplant. 2016 Oct;51(10):1397-1399. doi: 10.1038/bmt.2016.134. Epub 2016 May 23. No abstract available.

PMID:
27214072
27.

TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.

Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA.

Cancer Res. 2016 Apr 15;76(8):2087-93. doi: 10.1158/0008-5472.CAN-15-3352. Erratum in: Cancer Res. 2016 Oct 15;76(20):6130. Cancer Res. 2017 Jun 15;77(12 ):3379.

28.

Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Ben Taylor M, Bishton MJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS.

Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-1241. doi: 10.1016/j.bbmt.2016.03.034. Epub 2016 Apr 14.

29.

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C.

Science. 2016 Mar 25;351(6280):1463-9. doi: 10.1126/science.aaf1490. Epub 2016 Mar 3.

30.

A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation.

Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S.

Genome Med. 2015 Dec 15;7:128. doi: 10.1186/s13073-015-0246-z.

31.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Śledzińska A, Menger L, Bergerhoff K, Peggs KS, Quezada SA.

Mol Oncol. 2015 Dec;9(10):1936-65. doi: 10.1016/j.molonc.2015.10.008. Epub 2015 Oct 26. Review.

32.

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V.

Br J Haematol. 2016 Feb;172(3):360-70. doi: 10.1111/bjh.13802. Epub 2015 Nov 18.

PMID:
26577457
33.

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS.

Blood. 2015 Dec 24;126(26):2781-9. doi: 10.1182/blood-2015-08-664755. Epub 2015 Oct 27.

34.

Recent advances in antibody-based therapies for Hodgkin Lymphoma.

Peggs KS.

Br J Haematol. 2015 Oct;171(2):171-178. doi: 10.1111/bjh.13578. Epub 2015 Jul 17. Review.

PMID:
26184792
35.

Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin Lymphoma.

Gohil SH, Ardeshna KM, Lambert JM, Pule MA, Mohamedbhai S, Virchis A, Morris EC, Linch DC, Thomson KJ, Peggs KS.

Br J Haematol. 2015 Oct;171(2):197-204. doi: 10.1111/bjh.13561. Epub 2015 Jun 26.

PMID:
26119524
36.

Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles.

Marzolini MA, Thomson KJ, Peggs KS.

Br J Haematol. 2016 Jan;172(2):285-7. doi: 10.1111/bjh.13474. Epub 2015 May 5. No abstract available.

PMID:
25939287
37.

Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report.

Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J.

Cancer Immunol Immunother. 2015 Jun;64(6):765-7. doi: 10.1007/s00262-015-1689-1. Epub 2015 Apr 1.

PMID:
25828465
38.

Cytomegalovirus-specific T-cell therapies: current status and future prospects.

Nicholson E, Peggs KS.

Immunotherapy. 2015;7(2):135-46. doi: 10.2217/imt.14.99. Review.

PMID:
25713989
39.

Reprint of: Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

Boeckh M, Murphy WJ, Peggs KS.

Biol Blood Marrow Transplant. 2015 Feb;21(2 Suppl):S19-24. doi: 10.1016/j.bbmt.2014.12.034. Review.

40.

Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing.

Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, Gant V, Chiu CY.

Clin Infect Dis. 2015 Mar 15;60(6):919-23. doi: 10.1093/cid/ciu912. Epub 2015 Jan 7.

41.

CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status.

Sellar RS, Vargas FA, Henry JY, Verfuerth S, Charrot S, Beaton B, Chakraverty R, Quezada SA, Mackinnon S, Thomson KJ, Peggs KS.

Blood. 2015 Jan 22;125(4):731-9. doi: 10.1182/blood-2014-07-589150. Epub 2014 Dec 12.

42.

Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.

Boeckh M, Murphy WJ, Peggs KS.

Biol Blood Marrow Transplant. 2015 Jan;21(1):24-9. doi: 10.1016/j.bbmt.2014.11.002. Epub 2014 Nov 11. Review.

43.

An antitumor boost to TH9 cells.

Quezada SA, Peggs KS.

Nat Immunol. 2014 Aug;15(8):703-5. doi: 10.1038/ni.2945. No abstract available.

PMID:
25045872
44.

A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy.

Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada SA, Peggs KS, Pule M.

Blood. 2014 Aug 21;124(8):1277-87. doi: 10.1182/blood-2014-01-545020. Epub 2014 Jun 26.

45.

Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.

Furness AJ, Vargas FA, Peggs KS, Quezada SA.

Trends Immunol. 2014 Jul;35(7):290-8. doi: 10.1016/j.it.2014.05.002. Epub 2014 Jun 18. Review.

PMID:
24953012
46.

Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.

Sellar RS, Peggs KS.

Expert Opin Biol Ther. 2014 Aug;14(8):1121-6. doi: 10.1517/14712598.2014.908847. Epub 2014 Apr 25. Review.

PMID:
24762099
47.

Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.

Kothari J, Peggs KS, Bird A, Thomson KJ, Morris E, Virchis AE, Lambert J, Goldstone AH, Linch DC, Ardeshna KM.

Br J Haematol. 2014 May;165(3):334-40. doi: 10.1111/bjh.12741. Epub 2014 Jan 18.

PMID:
24438080
48.

Emerging options for the treatment of melanoma - focus on ipilimumab.

Roddie C, Peggs KS.

Immunotargets Ther. 2014 Mar 17;3:67-78. doi: 10.2147/ITT.S43522. eCollection 2014. Review.

49.

EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M, Lim Z, Cook G, Carpenter B, Pettitt AR, Mathew S, Connelly-Smith L, Yin JA, Viskaduraki M, Chakraverty R, Orchard K, Shaw BE, Byrne JL, Brookes C, Craddock CF, Chaganti S.

Bone Marrow Transplant. 2014 Feb;49(2):280-6. doi: 10.1038/bmt.2013.170. Epub 2013 Nov 11.

PMID:
24212561
50.

Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.

Gerlinger M, Quezada SA, Peggs KS, Furness AJ, Fisher R, Marafioti T, Shende VH, McGranahan N, Rowan AJ, Hazell S, Hamm D, Robins HS, Pickering L, Gore M, Nicol DL, Larkin J, Swanton C.

J Pathol. 2013 Dec;231(4):424-32. doi: 10.1002/path.4284.

Supplemental Content

Loading ...
Support Center